ISSN:
1569-8041
Keywords:
paclitaxel
;
quality-of-life
;
recurrent high-grade glioma
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background:The prognosis of malignant gliomas remains poor. Inrecurrent disease, chemotherapy can be considered. Patients and methods:In this phase II study we determined theanti-tumour efficacy of paclitaxel 200 mg/m2 in a three-hourintravenous infusion every three weeks in chemonaïve patients withrecurrent high-grade glioma in terms of response, survival, and quality oflife. Results:In 17 patients (14 glioblastoma multiforme, 3 anaplasticastrocytoma) 69 paclitaxel cycles were administered. Partial or completeresponses were not observed. Stable disease for four to six months wasobserved in five patients (29%). Median time to progression and mediansurvival were two and 10 months, respectively. Toxicity due to paclitaxel wasas to be expected and minor in most cases. Quality of life and mood estimatesappeared rather stable over time. Conclusions:We conclude that three-weekly 200 mg/m2paclitaxel chemotherapy for patients with recurrent high-grade gliomas did notlead to major complications or adverse effects on quality of life and mood.However, this therapy is of only very limited value in terms of response andsurvival in such patients.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008376123066
Permalink
